Hypertension, Portal
Cardiovascular
2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Boehringer IngelheimAvenciguat
Galectin TherapeuticsGR-MD-02
Clinical Trials (2)
Total enrollment: 80 patients across 2 trials
A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)
Start: Apr 2022Est. completion: Jun 202480 patients
Phase 2Terminated
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Start: Jun 2015Est. completion: Oct 2017
Phase 2Completed
Related Jobs in Cardiovascular
Embedded Software and System Test Engineer (H/F)
Cardiawave
Levallois-Perret, France (Hybrid)
Just now
Territory Sales Manager - Iowa / Nebraska
HeartFlow
Cedar Rapids, IA; Des Moines, IA; Omaha, NE; Lincoln, NE
Yesterday
From $150K/yr
Associate Regulatory Affairs Specialist
Medtronic
Mounds View, Minnesota, United States of America
Yesterday
$60K - $90K/yr
Business Development Manager, Post Transplant, Cardio Thoracic
Thermo Fisher Scientific
Remote
Yesterday
Director, Medical Affairs
Abbott
Germany - Hesse - Eschborn
Yesterday
Therapy Development Manager
Abbott
Australia > Doncaster : 666 Doncaster Road
Yesterday
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space